Vaccine Clinical Trial

Vaccine research is unique in its ability to have widespread impact on global health. Now more than ever, vaccine development requires a more innovative and efficient approach. Our vaccine service scope covers vaccine clinical design, monitoring, data statistics and biological testing, we work closely with you to develop personalized roadmaps for your vaccine study and aims to maximize efficiency, anticipate challenges, and mitigate risk.

Clinical operation experience across APAC, Europe, Latin America and Africa.
Supported the first Chinese vaccine to obtain clearance for a Phase I clinical trial in US.
Conducted multiple Phase III protective efficacy studies for innovative vaccines, including chickenpox, RSV, S. aureus, and therapeutic BCG.

30+

Non-Covid vaccine clinical studies

150K

Enrolled subjects in global vaccine studies

70+

Approved vaccines we served

14

Covid-19 clinical studies

50%

Percentage of Phase III studies

16

Provincial CDCs in collaboration

A Broad Range of Expertise

S. aureus

Zoster

Covid-19

Therapeutic BCG

Influenza

Malaria

Rabies

Nasopharyngeal Cancer

Hepatitis B

Poliomyelitis

Rotavirus

Live Attenuated Varicella

ECM

HIV

HPV

Mumps

Vaccine Clinical Research Process

Team Organization

Documents and SOP Preparation

Base Setup

IEC reviewing

HGRAC & Agreement

Site Initiation

Enrollment & Monitoring

Data clean & Database Lock

Site Close Out

A Unique Partner for Vaccine Clinical Trials

Long-term, strong cooperative relationships with various CDCs and global sites enabling rapid start-up, predictability and fast enrollment
A comprehensive set of services & capabilities covering Phase I-IV trials at a global level
Strong experience working on COVID-19 treatments since February 2020 with dedicated COVID-19 vaccine project team and successful delivery experience
Ongoing vaccine MRCT projects cover 10+ countries in APAC, Europe, Latin America and Africa with 140,000+ subjects enrolled
Regulatory engagement for planning and study start-up worldwide, supported by country-specific regulatory specialists

Case Study

From late 2020 to early 2021, Tigermed teamed up with CanSinoBio and Pakistan local expert, as well as clinical professionals from Mexico, Russia, Chile, Argentina, to conduct Phase III trial of COVID-19 vaccine and ultimately delivered the study. This is also the first China-initiated phase III vaccine clinical study covering multiple continents, including Asia, Europe, and Latin America.

Read press release here

Let's Connect for a Conversation